GLS Pharma Ltd

Lung cancer is a major cause of morbidity and mortality and the majority of new cases are advanced non–small-cell lung cancer (NSCLC).

Lung cancer is a major cause of morbidity and mortality and the majority of new cases are advanced non–small-cell lung cancer (NSCLC). The epidermal growth factor receptor (EGFR) has a pivotal role in tumorigenesis with many human cancers over expressing EGFR including up to 80% of NSCLCs. Over expression of EGFR is associated with advanced disease and poor survival. Erlotinib is a highly potent, orally active EGFR tyrosine-kinase inhibitor (TKI) that has shown significant antitumor activity.

Indications

• Erlotinib is prescribed as initial treatment for patients with NSCLC whose cancer has spread to other parts of the body and that has certain types of epidermal growth factor receptor (EGFR) mutations. (1st-line treatment)
• Prescribed as 2nd- or 3rd-line treatment for advanced-stage NSCLC in patients whose cancer has spread or grown after receiving at least one round of chemotherapy.
• Erlotinib in combination with gemcitabine is prescribed for patients with advanced-stage pancreatic cancer whose cancer has spread, grown, or cannot be surgically removed and who have not received previous chemotherapy.